<DOC>
	<DOCNO>NCT00334932</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride liposome melphalan , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving doxorubicin hydrochloride liposome melphalan together bortezomib may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose doxorubicin hydrochloride liposome , melphalan , bortezomib see well work treat patient relapsed refractory stage I , stage II , stage III multiple myeloma .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome , Melphalan , Bortezomib Treating Patients With Relapsed Refractory Stage I , Stage II , Stage III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability doxorubicin HCl liposome , melphalan , bortezomib patient relapse refractory stage I-III multiple myeloma . - Determine maximum tolerate dose ( MTD ) regimen patient . Secondary - Determine overall response rate , include complete , near-complete , partial , minimal response rate , patient treat regimen . - Determine time response , progression-free survival , overall survival patient treat regimen . - Determine toxic effect regimen MTD patient . OUTLINE : This multicenter , phase I , dose-escalation study follow phase II study . - Phase I : Patients receive doxorubicin HCl liposome IV 30-60 minute melphalan IV 30 minute day 1 bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos doxorubicin HCl liposome , melphalan , bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 4 6 patient experience dose-limiting toxicity 2 course therapy . - Phase II : Patients receive doxorubicin HCl liposome , melphalan , bortezomib MTD phase I . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : Approximately 32 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Stage I , II , III disease accord DurieSalmon stag criterion Progressive disease , define one following : For secretory disease : A 25 % increase serum Mprotein Bence Jones protein ( absolute increase 0.5 g/dL serum Mprotein ≥ 200 mg/24 hour urine light chain excretion ) For nonsecretory disease : Bone marrow biopsy &gt; 25 % increase plasma cell absolute increase ≥ 10 % prior know level Development new worsen exist lytic bone lesion soft tissue plasmacytoma Hypercalcemia ( i.e. , calcium &gt; 11.5 mg/dL ) Relapsed complete response Must receive ≥ 2 follow therapeutic regimen multiple myeloma : Nonmyeloablative transplantation No significant graftversushost disease At least 30 day since prior immunosuppressive therapy ( concurrent prednisone allow provide dose ≤ 10 mg daily ) Mobilization chemotherapy follow either single tandem autologous stem cell transplantation ( consider 1 prior regimen ) Mobilization chemotherapy follow autologous subsequent nonmyeloablative allogeneic stem cell transplantation ( consider 1 prior regimen ) Any combination drug give concurrently ( consider 1 prior regimen ) PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Absolute neutrophil count &gt; 1,000/mm^3 ( colonystimulating factor ) Platelet count &gt; 50,000/mm^3 ( transfusion support ) Bilirubin ≤ 2.0 mg/dL AST ≤ 4 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week completion study treatment No history allergic reaction compound contain boron mannitol No active uncontrolled viral ( include HIV ) , bacterial , fungal infection No motor sensory neuropathy ≥ grade 2 No myocardial infarction within past 6 month No New York Heart Association class III IV heart failure No uncontrolled angina No severe uncontrolled arrhythmia No acute ischemia EKG LVEF ≥ 35 % MUGA ( MUGA require patient whose lifetime cumulative doxorubicin hydrochloride dose &gt; 400 mg/m^2 ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No grade III IV toxicity due previous antineoplastic therapy ( except alopecia ) At least 3 week since prior chemotherapy No prior doxorubicin HCl liposome , melphalan , bortezomib combination therapy ( single twodrug combination allow ) No concurrent corticosteroid ( ≤ 10 mg prednisone/day equivalent allow ) No concurrent chemotherapy No concurrent thalidomide No concurrent investigational therapy No concurrent antineoplastic treatment multiple myeloma , include clarithromycin No concurrent radiation therapy No concurrent nonsteroidal antiinflammatory agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>